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Background: The most commonly reported symptom of hyperthyroidism is weight loss; 26 
successful treatment increases weight. Weight gain faced by patients with hyperthyroidism is 27 
widely considered as a simple re-accumulation of premorbid weight, whereas many patients 28 
feel there is a significant weight "overshoot" attributable to the treatment. We aimed to 29 
establish if weight gain seen following treatment for hyperthyroidism represents replenishment 30 
of premorbid weight or "overshoot" beyond expected regain and, if there is excessive weight 31 
gain, whether this is associated with the applied treatment modality. 32 
Methods: We calculated the risk of becoming obese (BMI>30 kg/m2) following treatment for 33 
hyperthyroidism by comparing body mass index (BMI) of 1373 patients with overt 34 
hyperthyroidism seen in a secondary care setting with the age- and sex-matched background 35 
population (Health Survey for England (2007-2009)). Next, we investigated the effect of 36 
treatment with antithyroid drug alone in regard to antithyroid drug with radioiodine therapy. 37 
We modelled the longitudinal weight data in relation to the treatment pathway to thyroid 38 
function and the need for long-term thyroxine replacement.  39 
Results: During treatment of hyperthyroidism, men gained 8.0 kg (SD±7.5) and women 5.5 kg 40 
(±6.8). At discharge, there was a significantly increased risk of obesity in male (OR=1.7, 41 
95%CI 1.3–2.2, P<0.001) and female (1.3, 1.2–1.5, P<0.001) patients with hyperthyroidism 42 
compared with the background population. Treatment with radioiodine was associated with 43 
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additional weight gain (0.6 kg, 0.4–0.8, P<0.001), compared with antithyroid drug treatment 44 
alone. More weight gain was seen if serum TSH was markedly increased (TSH>10 mIU/L; 0.5 45 
kg, 0.3–0.7, P<0.001) or free thyroxine was reduced (fT4 ≤10 pmol/L (0.8 ng/dl); 0.3 kg, 0.1–46 
0.4, P<0.001) during follow-up. Initiation of levothyroxine was associated with further weight 47 
gain (0.4 kg, 0.2–0.6, P<0.001) and the predicted excess weight gain in radioiodine-induced 48 
hypothyroidism was 1.8 kg. 49 
Conclusions: Treatment for hyperthyroidism is associated with significant risks of becoming 50 
obese. Radioiodine treatment and subsequent development of hypothyroidism were associated 51 
with small but significant amounts of excess weight gain compared with antithyroid drugs 52 
alone. We advocate that the discussion over the weight "overshoot" risk forms part of the 53 
individualized treatment decision making process.  54 




Hyperthyroidism, characterized by excess concentrations of circulating thyroid hormones, 57 
commonly presents with weight loss, often despite increased appetite and caloric intake (1). 58 
Weight regain may therefore be expected following normalization of thyroid function. 59 
However, it is not clear if this weight regain reflects the desirable replenishment of premorbid 60 
weight or an undesirable “overshoot” potentially contributing to increased risks of obesity. 61 
Since hyperthyroidism is a common condition, affecting 3% of women and 0.3% of men in the 62 
UK (2–4), and is associated with increased morbidity and mortality (5,6), especially from 63 
cardiovascular causes, weight control in this group of patients is an important public health 64 
issue. Presently, it is not clear if treatment of hyperthyroidism is a risk factor for development 65 
of obesity; hence, no weight management interventions are routinely offered in clinical 66 
practice.  67 
Three main modalities are employed to treat hyperthyroidism – antithyroid drugs, 68 
administration of radioiodine (131-I), or thyroidectomy. While treatment with drugs is 69 
associated with higher recurrence rates, 131-I and thyroidectomy most often result in 70 
hypothyroidism and the need for life-long levothyroxine replacement. Since no single 71 
treatment modality is obviously superior, guidelines recommend discussion of all therapeutic 72 
options between the patient and the clinician allowing final individualized shared decision 73 
making (7,8). However, when treatment options are discussed, patients with hyperthyroidism 74 
frequently express concern that the administration of radioiodine will result in excessive weight 75 
gain, often determining that this is a less favored therapeutic option.  76 
Several studies have indicated that the increased risk of mortality in hyperthyroidism is 77 
mitigated following induction of hypothyroidism with 131-I and guidelines recommend that 78 
doses sufficient to induce hypothyroidism should be administered (8–11). Some smaller studies 79 
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(12) have proposed the initiation of levothyroxine replacement as an additional risk for 80 
becoming obese, a finding not confirmed by others (13). Importantly higher body weight in 81 
patients treated with levothyroxine has been linked to reduced quality of life (14). There are no 82 
large studies that systematically assess the impact of the chosen treatment modality on weight 83 
changes in patients with hyperthyroidism. 84 
We set out to determine whether treatment of hyperthyroidism is associated with increased 85 
risks of becoming obese in a large hospital cohort presenting with a first episode of overt 86 
hyperthyroidism to a single specialist clinic based on comparison with the age- and sex-87 
matched English background population. We evaluated the extent of weight gain following 88 
treatment of hyperthyroidism and examined the influence of the treatment modality used (131-89 
I or antithyroid drugs), development of hypothyroidism and biochemical control of 90 
hyperthyroidism, on the likelihood of weight gain. 91 
Patients and methods 92 
We studied weight changes in patients registered in the Thyroid Clinic Database at the 93 
University Hospitals Birmingham NHS Foundation Trust. Data on all adult patients with newly 94 
diagnosed overt hyperthyroidism and treated either with antithyroid drugs (ATD), 95 
administration of radioiodine (131-I) or a combination of both between 2000 and 2014 were 96 
extracted, allowing up to 36 months for follow-up (study period 01/01/2000–30/06/2017). 97 
Overt hyperthyroidism was defined as raised serum free T4 (fT4) and/or free tri-iodothyronine 98 
(fT3) with undetectable serum thyrotrophin (TSH). Further inclusion criteria encompassed a 99 
minimum duration of follow-up of six months and a minimum of four recorded weight 100 
measurements (with recording of clinic weights at presentation and discharge mandatory), a 101 
measurement of patients’ height and a confirmed successful outcome at discharge, which was 102 
defined as (i) normal serum TSH concentrations off any medication for at least six months 103 
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following discontinuation of ATD or following 131-I, or (ii) start of levothyroxine replacement 104 
therapy for hypothyroidism. Patients treated with antithyroid drugs long-term were excluded. 105 
From the cohort of 1604 eligible patients, we excluded those with transient hyperthyroidism 106 
due to thyroiditis (n=30) and those with amiodarone-induced thyrotoxicosis (n=22). 107 
Additionally, we excluded patients with potentially unstable weight due to causes unrelated to 108 
hyperthyroidism: pregnancy or within 12 months postpartum (n=123), or death during the 109 
study period (n=56).  110 
The final study cohort thus comprised 1373 patients aged between 18 to 90 years. The project 111 
was approved and registered by the University Hospitals Birmingham NHS Foundation Trust 112 
(CARMS-11842). 113 
Patients were categorized by simple clinical and immunological criteria into three diagnostic 114 
groups: Graves’ disease, toxic nodular hyperthyroidism and hyperthyroidism of indeterminate 115 
etiology. Graves’ disease was defined as presence of biochemical hyperthyroidism with at least 116 
two of: palpable diffuse goiter, significant titer (>1:100) of thyroid peroxidase and/or presence 117 
of thyroid eye disease as previously described (1,11). Additionally, 10% (139/1373) of patients 118 
had TSH-receptor antibodies (TRAb) measured following routine implementation of this assay 119 
(ELISA Assay by Thermo Scientific B.R.A.H.M.S (Hennigsdorf, Germany)) in April 2013 and 120 
TRAb titers >1 IU/L were considered indicative of Graves’ disease. Toxic nodular 121 
hyperthyroidism was defined as hyperthyroidism in the presence of palpable nodular goitre. 122 
Patients who did not fulfil either of these criteria were categorized indeterminate, representing 123 
a mixed group with Graves’ disease, toxic nodular hyperthyroidism or both, the size of this 124 
group reflecting our policy of not performing routine radionuclide imaging in patients 125 
presenting with hyperthyroidism. 126 
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The following demographic factors were recorded at presentation: sex, age at diagnosis 127 
(divided into quartiles: 18–36 years, 37–47 years, 48–60 years, 61–90 years) and height (m). 128 
Clinical data collected during initial examination comprised significant past medical history, 129 
current drug therapy, smoking status (current smoker/non-smoker), as well as the presence, 130 
size and type of goiter. Patients were requested to assess their weight change prior to 131 
presentation, categorized as weight loss, weight gain or unchanged.  132 
Weight (kg) was recorded at presentation and during each follow-up visit as part of our routine 133 
clinic protocol. Body mass index (BMI, kg/m2) was calculated and divided according to the 134 
International Classification (15) into underweight: <18.5 kg/m2; normal weight 18.5–25.0 135 
kg/m2; overweight 25.1–30.0 kg/m2 and obese ≥30.1 kg/m2. The underweight and normal 136 
weight categories were combined and analyzed together due to the small number of 137 
underweight patients (44 at initial and 16 at discharge visit). 138 
Laboratory measurements included serial concentrations of serum fT4 (reference range: 10–22 139 
pmol/L (0.8–1.7 ng/dL)), TSH (0.30–4.50 mIU/L) and serum fT3 (3.5–6.5 pmol/L (0.23–0.42 140 
ng/dL)) at presentation. The serum fT4 concentration at diagnosis (used as a marker of disease 141 
severity) was categorized into: 22.1–30.0, 30.1–40.0, 40.1–60.0, ≥60.1 pmol/L (1.7–2.3, 2.3–142 
3.1, 3.1–4.7, ≥4.7 ng/dL). A fifth category was added to account for patients with T3 143 
thyrotoxicosis (fT3 >6.5 pmol/L (>0.42 ng/dL)) (N=57), whose serum fT4 was within the 144 
normal range (≤22.0 pmol/L (≤1.7 ng/dL)). Serum concentrations of fT4 during follow-up were 145 
categorized as follows: below normal (≤10.0 pmol/L (≤0.8 ng/dL)), normal (10.1–22.0 (0.8–146 
1.7)), raised (22.1–30.0 (1.7–2.3)), high (30.1–40.0 (2.3–3.1)), and markedly high (≥40.1 147 
(>3.1)). Serial TSH concentrations were categorized as undetectable (≤0.10 mIU/L), low but 148 
detectable (0.11–0.30 mIU/L), normal (0.31–4.50), slightly raised (4.51–10.00), and markedly 149 
raised (≥10.01). Clinical measurements were censored at 36 months of follow-up irrespective 150 
of whether patients were discharged.  151 
8 
 
Treatment of hyperthyroidism 152 
Patients were offered treatment with antithyroid drugs (ATD) or with radioiodine (131-I) 153 
according to local, national (16) and international (7) guidelines. Patients typically commenced 154 
a single dose of 20 mg carbimazole (CMZ) or twice-daily doses of 100 mg propylthiouracil 155 
(PTU). A dose titration regimen was employed in all, with typical maintenance doses of 5–156 
10 mg carbimazole or 50–100 mg propylthiouracil daily. Patients were monitored every 6–8 157 
weeks until control of hyperthyroidism and then every three months until discharge. Patients 158 
with Graves’ disease who relapsed after a 12–18 month course of ATD were advised to undergo 159 
131-I therapy. Prior to 131-I, patients received antithyroid drugs to control hyperthyroidism; 160 
ATD were stopped at least one week before 131-I and not restarted sooner than one week after. 161 
Following 131-I, patients were seen at 6–8 week intervals for a minimum of six months. They 162 
were discharged with no medication if thyroid function remained normal for at least 6 months 163 
(euthyroid outcome) or they were prescribed life-long levothyroxine replacement once 164 
permanent hypothyroidism developed. Those remaining hyperthyroid six months after 131-I 165 
were offered a second dose and if they declined, they were treated with ATD (11).  166 
Background population 167 
We compared patients' BMI (categorical and continuous) with background population data 168 
obtained from the Health Survey (HSE) for England (17). To account for the decreasing trend 169 
in the proportion of people with healthy BMI in England over the years, median years of 170 
presentation and discharge from the clinic were calculated, which were 2007 and 2009, 171 
respectively. We combined data from survey years 2007 to 2009, retrieving 22,726 records 172 
with valid BMI. To make data more comparable, we excluded survey participants younger than 173 
18 years (n=664) and older than 90 years (n=53) and performed frequency matching (1:8) with 174 
no replacement based on sex and age categories defined for the patients. Altogether, data of 175 
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10,984 survey participants were used for comparison purposes. The methodology of HSE data 176 
collection is described elsewhere (18). 177 
Statistical analysis 178 
Demographic and clinical characteristics of the cohort were described using means and 179 
standard deviations (SD) for continuous variables and counts and proportions for discrete 180 
variables. Statistical significance was set a priori at the 5% level.  181 
Patients’ and background population's BMI were compared as categorical and continuous 182 
measurements. Proportions were used to calculate odds ratios as crude values and adjusted for 183 
smoking habit.  184 
In longitudinal analysis of weight gain depending on treatment received, missing weight data 185 
was imputed as a mean of nearby points corrected for the time between the measurements. 186 
Missing self-reported weight change data prior to diagnosis were coded as a separate category. 187 
In cases of any other missing observations (smoking, goiter, thyroid eye disease), an 188 
assumption of absence of the characteristics was made.  189 
A Generalized Estimating Equation linear model, which allowed for clustering within patients, 190 
was developed to investigate the relationship between weight and demographic and clinical 191 
measurements.  Time-variant covariates entered into the model included duration of follow-up 192 
(months), serum fT4 and TSH concentration at each clinic visit, 131-I treatment and 193 
levothyroxine treatment. The model used an autoregressive working correlation matrix with 194 
robust standard errors. Our main variables of interest were those associated with treatment 195 
(131-I with or without subsequent levothyroxine compared to antithyroid drugs only) and 196 




Due to the number of patients categorized as having hyperthyroidism of indeterminate etiology, 199 
the sensitivity of the findings was investigated by comparing model coefficients with and 200 
without those patients. A further sensitivity analysis sensitivity analysis was undertaken 201 
excluding patients with current oral or inhaled corticosteroid use (n=26 patients) in view of 202 
well-documented effects of steroids on weight changes (19). The statistical analyses were 203 
performed in IBM SPSS Statistics (version 24). 204 
 205 
Results 206 
Characteristics of patient population 207 
The baseline characteristics of 1373 patients in the cohort are presented in table 1. Mean 208 
duration of follow-up was 23 (±8.6) months. 573 patients received ATD only and 800 209 
underwent treatment with radioiodine which resulted in permanent hypothyroidism in 571 210 
(78% of those undergoing 131-I therapy).  211 
Comparison of weight status in hyperthyroid cohort compared with the background 212 
population 213 
The matched background population consisted of 10,984 participants surveyed between 2007 214 
and 2009. The matching resulted in the same proportion of men to women (23% men and 77% 215 
women) and in similar age (49 [±16.4] vs. 48 [±16.4] years, respectively) of clinic patients 216 
compared with the background population. There was, however, a difference in smoking habits 217 
among men (32.7% male patients were smokers compared with 22.7% of the male background 218 
population, P<0.001) but not among women (21.3% vs. 21.2%; P=0.48).  219 
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At presentation, there were larger proportions of healthy/underweight male (46% vs. 30%, 220 
P<0.001) and female patients (49% vs. 41%, P<0.001) and smaller proportions of the obese 221 
compared to the background population (18% vs. 26%, P<0.001 for men; 19% vs. 26%, 222 
P<0.001 for women), likely reflecting the loss of weight prior to treatment for hyperthyroidism 223 
(Figure 1, panel A).  224 
At discharge, the proportions of obese male (37% vs. 26%, P<0.001) and female (32% vs. 26%, 225 
P<0.001) patients with hyperthyroidism were significantly higher compared with the control 226 
male and female population. The odds of becoming obese were increased for both male (1.7 227 
[1.3–2.2], P<0.001) and female patients (1.3, [1.2–1.5], P<0.001). The odds ratio estimates for 228 
obesity remained similar for both sexes after adjustment for smoking habits. The increases in 229 
proportions of obese patients were compensated by significantly less patients of both sexes 230 
with healthy/underweight BMI at the end of the treatment (23% vs. 30%, P<0.001 for men and 231 
35% vs. 41%, P<0.001 for women) (Figure 1, panel B). Patients' BMI expressed as continuous 232 
values at discharge were significantly higher than those in background population (men: 233 
median 28.4 kg/m2 [IQR: 25.5–31.8], vs. 27.1 kg/m2 [24.5–31.2], P<0.001; women: 27.2 kg/m2 234 
[23.8–31.2] vs. 26.1 kg/m2 [23.2–31.2] P<0.001). 235 
  236 
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Weight changes during follow-up  237 
The mean weight gain in the cohort of patients with hyperthyroidism was 6.0 (±7.1) kg. A 238 
weight increase of ≥5% was observed in 896 (65%) and of ≥10% in 526 (38%) patients, when 239 
comparing body weight at discharge and at presentation. 240 
Men gained significantly more weight than women (Table 2) as did patients with Graves' 241 
disease compared to either those with toxic nodular hyperthyroidism or to those with 242 
indeterminate etiology. The extent of weight gained correlated with the severity of 243 
hyperthyroidism at presentation and patients with Graves’ disease had higher fT4 compared 244 
with those with toxic nodular disease (54.7 pmol/L, SD 24.9 vs 39.4 pmol/L, 19.1). Patients 245 
who reported weight loss prior to diagnosis gained significantly more than the other groups; 246 
however, small amounts of weight gain were noted equally in those who reported weight gain 247 
or no weight change prior to treatment and in patients with no recorded weight changes. 248 
Cigarette smokers at presentation gained more at the end of treatment. Whether the final weight 249 
change was influenced by change in smoking habit is not clear as such data was not recorded 250 
during follow-up.  251 
Figure 2 illustrates the mean percentage weight change in all patients during follow-up. Weight 252 
gain was most pronounced during the first six months following presentation, when a mean 253 
increase of 5% of baseline weight was observed. Weight gain continued throughout the period 254 
of follow-up and reached a mean of 10% increase at 24 months after presentation, which 255 
continued until the end of study. 256 
Weight changes in relation to treatment  257 
Over the period of treatment and follow-up, patients undergoing medical therapy only (N=573) 258 
gained on average 5.4 kg (±7.1), those remaining euthyroid following 131-I (N=229) gained 259 
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5.2 kg (±6.6) and patients who developed hypothyroidism following 131-I (N=571) gained 7.1 260 
kg (±7.0). Those with 131-I-induced hypothyroidism gained significantly more than those 261 
remaining euthyroid following131-I (1.9 kg, 95%CI: 0.6–3.3) or those treated with ATD only 262 
(1.7 kg, 0.7–2.8). The difference in weight gain between ATD only treated patients and those 263 
euthyroid following 131-I was statistically insignificant (0.2 kg, -1.2–1.5). Univariate analysis 264 
of weight gain within particular demographic and clinical categories is presented in 265 
Supplementary table 1. 266 
The multivariable longitudinal analysis demonstrated that 131-I treatment was associated with 267 
a small but significant additional weight gain (0.6 kg, P<0.001), compared with ATD alone 268 
(Table 3). Raised TSH (0.5 kg, P<0.001) and low fT4 measurements (0.3 kg, P<0.001) during 269 
follow-up were associated with significantly more weight gain compared with thyroid function 270 
within the normal range during follow-up. In addition to development of hypothyroidism 271 
(raised TSH concentrations and below normal fT4), the start of levothyroxine replacement was 272 
associated with an additional small but significant weight increase (0.4 kg, P<0.001). On the 273 
contrary, uncontrolled and prolonged thyrotoxicosis, indicated by high serial concentrations of 274 
serum fT4 as well as undetectable or below normal serum TSH concentrations were associated 275 
with less weight gain. 276 




Based on our model, we predict that a typical patient, whose hyperthyroidism would be 279 
controlled with antithyroid drug pre-treatment, who would undergo 131-I therapy and become 280 
overtly hypothyroid (confirmed by fT4 ≤10.0 pmol/L (≤0.8 ng/dL) and TSH ≥10.01 mIU/L) 281 
requiring levothyroxine replacement would, therefore, weigh around 1.8 kg more than the same 282 
patient treated with antithyroid drugs only and not developing hypothyroidism. Figure 3 283 
presents prediction of weight gain in a non-smoking female patient with Graves' disease 284 
presenting with weight loss and fT4 between 30.1 and 40.0 pmol/L (2.3–3.1 ng/dL) treated 285 
with (i) antithyroid drugs alone, (ii) I-131, not developing hypothyroidism, or (iii) I-131, 286 
subsequently developing hypothyroidism requiring levothyroxine treatment. 287 
Sensitivity analysis excluding patients with indeterminate etiology 288 
A sensitivity analysis was undertaken to test the model in patients with defined diagnoses of 289 
Graves’ disease or toxic nodular hyperthyroidism and excluding those with hyperthyroidism 290 
of indeterminate etiology (characteristics of sub-cohort are presented in supplementary table 291 
2). The analysis revealed similar findings and confirmed greater weight gain in patients treated 292 
with radioiodine compared with those receiving antithyroid drugs only (0.4 kg, P=0.02). Serum 293 
TSH ≥10 mIU/l (0.5 kg, P<0.001) and reduced fT4 (0.3 kg, P=0.001) were associated with 294 
significantly greater weight gain. Following adjustment for weight changes associated with 295 
fluctuation in thyroid hormone concentrations, further additional weight gain was observed if 296 
131-I resulted in permanent hypothyroidism requiring treatment with levothyroxine (0.5 kg, 297 
P<0.001). Raised serum fT4 concentrations during follow-up (-0.6 kg, -1.1, and -1.6 kg 298 
P<0.001 for fT4 22.1–30.0, 30.1–40.0 and >40 pmol/L (1.7–2.3, 2.3–3.1, >3.1 ng/dL), 299 
respectively) and below normal TSH concentrations (-0.8 kg, P<0.001 for undetectable TSH 300 
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and -0.4 kg, P=0.001 for low-but-detectable TSH 0.1–0.3) were associated with significantly 301 
less weight gain. The full model data is presented in supplementary table 3. 302 
Sensitivity analysis excluding patients using corticosteroids 303 
Since patients with autoimmune thyroid disease are at increased risk of other autoimmune 304 
diseases (19) and therefore may require treatment with corticosteroids which may affect weight 305 
changes, we performed a further sensitivity analysis excluding those currently using oral or 306 
inhaled steroids. Twenty-six patient (1.8%) reported corticosteroid use and their baseline 307 
characteristics are displayed in supplementary table 4. Steroid users were more likely to be 308 
aged over 60 years and to remain euthyroid following treatment with I-131.  Patients on steroids 309 
were more likely to present with fT4 concentrations between 30.1 and 40.0 pmol/L (2.3–3.1 310 
ng/dL), and were less likely to have well defined Graves’ disease. In view of these differences 311 
between steroid users and non-steroid users, we conducted a further sensitivity analysis 312 
excluding patients taking steroids and the results are displayed in supplementary table 5. The 313 
values of the explanatory variables have not changed, confirming robustness of our model. 314 
Discussion 315 
Principal findings 316 
Our large longitudinal study of patients treated for hyperthyroidism demonstrates significant 317 
weight gain following antithyroid treatment, especially during the initial six months of follow-318 
up but continuing for more than 24 months. Weight loss at presentation – seen in two-thirds of 319 
patients prior to diagnosis – resulted in significant weight increase during the course of 320 
treatment. However, weight regain significantly overshot the comparator background 321 
population average weight, contributing to the increased risk of becoming obese.  322 
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We quantified the amount of weight change following treatment for hyperthyroidism defined 323 
as the difference between the weight measurements taken during the initial visit to our clinic 324 
and the time of discharge to community, which was 8 kg for men and 5.5 kg for women. In 325 
some patients, antithyroid treatment was commenced in the community and by the time of 326 
clinic measurements some regain may have occurred. Whilst this may have affected our results, 327 
it is likely that our data underestimate the total weight gain following treatment for 328 
hyperthyroidism as the regain observed prior to the clinic visit was not captured. We confirmed 329 
more weight gain in men (20), in those with more severe hyperthyroidism (21,22) and in 330 
patients with Graves’ disease (23). The observed excessive weight gain in patients with Graves’ 331 
disease compared with toxic nodular hyperthyroidism may be in part related to a larger amount 332 
of weight loss prior to presentation as a consequence of more severe hyperthyroidism. However 333 
it is possible that appetite controlling signals are affected differently depending on the etiology 334 
of hyperthyroidism and further studies are required to explore these hypotheses.  335 
Weight gain and BMI increase have been linked with increased risk of development of 336 
parameters of the metabolic syndrome including hypertension, hypercholesterolemia and type 337 
2 diabetes mellitus (24–26). However there are no clear data relating to the exact impact of a 338 
1.1-1.3 unit difference in BMI as we observed when comparing our patients with the 339 
background population and the follow-up period in our study was not long enough to detect 340 
significant increases in development of these long term consequences. However since patients 341 
with hyperthyroidism are at increased risk of cardiovascular morbidity and mortality, further 342 
studies are required specifically assessing the risk of development of the metabolic syndrome 343 
in patients treated for hyperthyroidism. 344 
Our longitudinal model established time-varying changes in serum concentrations of thyroid 345 
hormones as significant factors influencing total weight change at the end of the study. TSH 346 
concentrations outside the normal range were significantly associated with weight alterations. 347 
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In particular, TSH levels above and fT4 below normal were associated with more weight gain. 348 
The extent of TSH abnormality correlated with the amount of observed weight change. 349 
Importantly, we demonstrated that the control of thyroid function during follow-up 350 
significantly influenced the total amount of weight change. Prolonged periods of increased 351 
serum fT4 and/or of reduced TSH concentrations resulted in less weight gain at 36 months of 352 
follow-up. Our findings are consistent with the strong correlation between alterations in thyroid 353 
hormone concentrations and changes in body weight found in children treated for Graves' 354 
disease (27). A large population study of healthy adults also showed that even small changes 355 
in thyroid function within the normal range may affect the BMI (28).  356 
We demonstrated that there was an overall modest (0.6 kg) but significant increase in weight 357 
gain in those treated with 131-I when compared to medical therapy alone. Additional 358 
significant increases were noted with development of hypothyroidism, indicated by reduced 359 
serum fT4 and raised TSH concentrations during follow-up, followed by levothyroxine 360 
replacement resulting in a further estimated amount of 1.2 kg weight gain. Similar findings 361 
were found in the sub-cohort of those with a defined etiology of hyperthyroidism.  362 
Results in relation to other studies 363 
Only a few smaller studies have compared the effect of different treatment modalities on weight 364 
gain. After one year of following up 65 patients undergoing one of three treatment modalities 365 
for hyperthyroidism, Pears et al. (29) found the highest increase in weight (7.4 kg) in patients 366 
receiving 131-I, which was 2 kg more than those treated with antithyroid drugs and 1.1 kg 367 
higher than those treated with thyroidectomy. In univariate analysis, Dale et al. (23) reported 368 
no difference in weight gain comparing antithyroid drugs with 131-I (5.2 vs. 4.8 kg) but 369 
patients treated with thyroidectomy gained significantly more (10.3 kg, P=0.007). These results 370 
were not confirmed in multivariable analyses, most likely due insufficient power (n=13 patients 371 
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undergoing thyroidectomy). In our study, analysing a much larger cohort, we were able to find 372 
a small but significant increase in weight gain in those treated with 131-I in comparison to 373 
medical treatment. 374 
Body weight is maintained by a fine-tuned balance between energy consumption and energy 375 
intake. Thyroid hormones have been reported to affect both. They influence thermogenesis 376 
(30), and formation of brown adipose tissue (31), as well as affecting resting energy 377 
expenditure by involuntary motor activity (32). Correlations between overfeeding/starvation 378 
and altered thyroid hormone production has also been reported (33). Additionally, the 379 
relationship between hormones regulating appetite and the thyroid is well established (34,35). 380 
All interplaying factors may be affected during and following the treatment for 381 
hyperthyroidism, although the exact mechanisms and specific effects of different antithyroid 382 
treatments remain elusive. 383 
Strengths and weaknesses of the study 384 
Our study is the first longitudinal systematic analysis of a large cohort followed up for a long 385 
period of time allowing the long-term weight gain. Detailed and complex statistical analyses 386 
included not only baseline factors but also time-varying effects of thyroid function, which 387 
significantly affect the weight gain and so far have not been accounted for. Our approach of 388 
matched comparison to a randomly selected background population allowed us, for the first 389 
time, to associate the treatment for hyperthyroidism with the increased risk of becoming obese.  390 
Nonetheless, our study is not free of the shortcomings. Firstly, our analysis is limited to two 391 
out of three treatment modalities for hyperthyroidism; those undergoing thyroidectomy were 392 
not included in the study. A further limitation of our study is the proportion of patients in whom 393 
the etiology of hyperthyroidism was indeterminate. This is in part due to the lack of earlier 394 
testing for TSH receptor antibodies, which would allow for better identification of Graves’ 395 
19 
 
disease. However, our sensitivity analysis including only patients with well-defined underlying 396 
diagnoses lends further support to the validity of our data. 397 
It would have been useful to study pre-morbid weight in relation to weight following 398 
completion of treatment. Due to the insidious nature of the condition and the prospective nature 399 
of the data collection, this was not obtainable. We did, however, collect data on self-reported 400 
weight changes compared with pre-morbid weights, as indicated in the tables and results 401 
sections. It is likely that these data are subjective and bias prone, which could, at least partially, 402 
explain the mean weight gain of 3.2 kg in those reporting no premorbid weight change. 403 
Due to the nature of treatment for hyperthyroidism, blinded randomized clinical trials, 404 
considered the golden standard of clinical research, are not feasible. Hence, we used a non-405 
randomized, observational design, in which causation has to be interpreted with caution.  406 
Conclusions 407 
Weight gain following treatment for hyperthyroidism with radioiodine or a 12-18 month course 408 
of antithyroid drugs is associated with increased risks of becoming obese. Radioiodine 409 
treatment was associated with a small but significant increase in weight compared to 410 
antithyroid drug alone. An additional increase was observed following induction of 411 
hypothyroidism, which is commonly associated with 131-I. Importantly, we observed 412 
significant effects of control of thyroid function on weight changes during follow-up. We 413 
postulate that discussion of the risk of excess weight gain should be undertaken and advocate 414 
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Weight (kg) at presentation 
mean (SD) 80.6 (16.5) 67.8 (15.0) 70.8 (16.3) 
Duration of follow-up (months)    
mean (SD) 22 (8.5) 23 (8.7) 23 (8.7) 
BMI category at presentation (kg/m2)    
mean (SD) 26.3 (4.6) 26.0 (5.3) 26.1 (5.2) 
Healthy/underweight (≤25.0) 145 (46%) 521 (49%) 666 (49%) 
Overweight (25.1–30.0) 117 (37%) 333 (32%) 450 (33%) 
Obese (>30.0) 56 (18%) 201 (19%) 257 (19%) 
Age at presentation (years)    
18–36 77 (24%) 267 (25%) 344 (25%) 
37–47 80 (25%) 274 (26%) 354 (26%) 
48–60 85 (27%) 259 (25%) 344 (25%) 
60–90 76 (24%) 255 (24%) 331 (24%) 
Etiology of hyperthyroidism    
Graves’ disease 140 (44%) 444 (42%) 584 (43%) 
Toxic nodular hyperthyroidism 31 (10%) 167 (16%) 198 (14%) 
Indeterminate etiology 147 (46%) 444 (42%) 591 (43%) 
Reported weight change    
No weight change 58 (18%) 218 (21%) 276 (20%) 
Weight loss 216 (68%) 643 (61%) 859 (63%) 
Weight gain 15 (5%) 95 (9%) 110 (8%) 
No data 29 (9%) 99 (9%) 128 (9%) 
Smoking status    
Non-smoker 214 (67%) 830 (79%) 1044 (76%) 
Smoker 104 (33%) 225 (21%) 329 (24%) 
Serum fT4 at presentation     
(pmol/L) (ng/dL)    
≤22.0 ≤1.7 10 (3%) 47 (4%) 57 (4%) 
22.1–30.0 1.7–2.3 71 (22%) 257 (24%) 328 (24%) 
30.1–40.0 2.3–3.1 69 (22%) 246 (23%) 315 (23%) 
40.1–60.0 3.1–4.7 93 (29%) 264 (25%) 357 (26%) 
≥60.1 ≥4.7 75 (24%) 241 (23%) 316 (23%) 
Treatment administered    
ATD only 103 (32%) 470 (45%) 573 (42%) 
131-I treatment (± ATD) 60 (19%) 169 (16%) 229 (17%) 
131-I (± ATD) and levothyroxine 155 (49%) 416 (39%) 571 (42%) 
Categorical data is presented as counts and proportions (%), continuous data as means and 533 
standard deviation (SD). BMI: Body Mass Index, fT4: free thyroxine, ATD: antithyroid drugs 534 
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Table 2: Mean weight change comparing initial and discharge weights (kg) and mean 535 
percentage weight change of initial body weight (%) 536 
 Patients with hyperthyroidism 
 N=1373 Weight change 
(kg) (95%CI) 
P value Weight change  
(%) (95%CI) 
P value 
Sex      




Female 1055 5.5 (5.1–5.9) 8.5 (7.9–9.1) 
BMI at presentation (kg/m2)       
Healthy/underweight (≤25.0) 666 6.2 (5.8–6.7)  10.5 (9.7–11.3)  
Overweight (25.1–30.0) 450  5.9 (5.2–6.6) 0.67 8.0 (7.0–8.9) <0.001 
Obese (>30.0) 257  6.0 (5.0–7.1)  6.7 (5.6–7.7)  
Age at presentation (years)     




37–47 354  6.2 (5.5–7.0) 9.6 (8.6–10.6) 
48–60 344  6.6 (5.9–7.3) 7.5 (6.5–8.6) 
≥61 331  5.0 (4.3–5.8) 9.7 (8.5–10.9) 
Etiology of hyperthyroidism     
Graves’ disease 584  7.4 (6.8–8.0)  10.8 (9.9–11.7)  
Toxic nodular 
hyperthyroidism 
198  4.4 (3.6–5.3) <0.001 
6.6 (5.3–8.0) 
<0.001 
Indeterminate etiology 591  5.3 (4.8–5.9)  7.9 (7.1–8.6)  
Smoking       




Current smokers 329  7.2 (6.4–8.1) 10.7 (9.5–11.9) 
Serum fT4 at presentation      
(pmol/L) (ng/dL)      
≤22.0 ≤1.7 57  3.1 (1.7–4.6) 
<0.001 
4.5 (2.5–6.5)  
22.1–30.0  1.7–2.3 328  3.8 (3.2–4.4) 5.5 (4.6–6.3)  
20.1–40.0 2.3–3.1 315  5.3 (4.7–6.0) 7.7 (6.7–8.6) <0.001 
40.1–60.0 3.1–4.7 357  6.6 (5.9–7.4) 9.8 (8.7–10.9)  
≥60.1 ≥4.7 316  9.1 (8.2–10.0) 13.6 (12.3–14.9)  
Weight change at presentation     




No weight change 276  3.2 (2.4–3.9) 4.5 (3.5–5.5) 
Weight gain 110  3.5 (2.3–4.7) 4.6 (3.0–6.1) 
No data recorded 128  4.6 (3.5–5.7) 6.5 (5.0–8.0) 
BMI: Body Mass Index, fT4: free thyroxine, 95%CI: 95% confidence interval 537 
 538 
  539 
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  Lower Upper 
 
Treated with I-131 0.4 0.2 0.6 <0.001 
On levothyroxine 0.6 0.4 0.8 <0.001 
Serial fT4 during follow-up     
(pmol/L) (ng/dL)     
≤10.0 ≤0.8 0.3 0.1 0.4 <0.001 
10.1–22.0 0.8–1.7 0    
22.1–30.0 1.7–2.3 -0.5 -0.7 -0.4 <0.001 
30.1–40.0 2.3–3.1 -1.1 -1.3 -0.8 <0.001 
≥40.1 ≥3.1 -1.6 -1.8 -1.3 <0.001 
Serial serum TSH (mIU/L)     
≤0.1 -0.8 -1.0 -0.7 <0.001 
0.11–0.30 -0.4 -0.5 -0.2 <0.001 
0.31–4.50 0    
4.51–10.00 0.1 0.02 0.3 0.02 
≥10.01 0.5 0.3 0.7 <0.001 
Age at presentation (years) 0.004 -0.01 0.02 0.58 
Initial weight (kg) 1.013 0.996 1.029 <0.001 
Length of follow-up (months) 0.41 0.37 0.44 <0.001 
Length of follow-up2 (months2) -0.008 -0.01 -0.007 <0.001 
Height (cm) -0.008 -0.04 0.02 0.59 
Female -0.9 -1.6 -0.3 <0.001 
Smoking (current/non-smoker) -0.5 -1.0 -0.02 0.04 
Reported weight change 
    
No weight change 0    
Weight gain 0.1 -0.6 0.9 0.73 
Weight lost 1.8 1.3 2.3 <0.001 
No data 0.7 -0.1 1.4 0.07 
Etiology of hyperthyroidism 
    
Graves' disease 0 
   
Toxic nodular  -0.6 -1.2 -0.005 0.05 
Indeterminate -0.7 -1.1 -0.2 <0.001 
 fT4 at presentation  
    
(pmol/L) (ng/dL)     
≤22 ≤1.7 -0.2 -1.0 0.5 0.56 
22.1–30.0 1.7–2.3 0 
   
30.1–40.0 2.3–3.1 0.5 0.0 1.0 0.03 
40.1–60.0 3.1–4.7 1.3 0.8 1.8 <0.001 
≥60.1 ≥4.7 2.3 1.7 3.0 <0.001 
The model presents the variables of interest in bold; the coefficients indicate predicted 542 
weight change (kg); the reference category is underlined. TSH: thyroid stimulating 543 





Figure 1: Body mass index in hyperthyroid patients compared to background population at 547 
time of initial visit (panel A) and at discharge (panel B). The error bars represent 95% 548 
confidence intervals 549 




Figure 2: Percentage mean weight change in the study cohort during the follow-up in six-552 
month intervals; whiskers represent 95% confidence intervals 553 




Figure 3: Modelling of predicted weight gain in a non-smoking female patient with Graves' 556 
disease presenting with weight loss and fT4 between 30.1 and 40.0 pmol/L (2.3–3.1 ng/dL) 557 
treated with (i) antithyroid drugs alone, (ii) I-131, not developing hypothyroidism, or (iii) I-558 
131, subsequently developing hypothyroidism requiring levothyroxine treatment. 559 
  560 
33 
 
Supplementary table 1: Mean weight change between initial and discharge weight (kg) 561 
within the treatment groups; P values were obtained with ANOVA for each category 562 
 ATD I-131 I-131 
+levothyroxine 
 
 Weight change (kg) (95%CI) P value 
Sex     
Male 8.3 (6.7–9.8)  6.3 (4.9–7.6)  8.5 (7.2–9.8) 0.129 
Female 4.8 (4.1–5.4)  4.8 (3.8–5.9)  6.6 (6.0–7.3) <0.001 
BMI at presentation (kg/m2)       
Healthy/underweight (≤25.0) 5.5 (4.8–6.2) 5.8 (4.4–7.3) 7.2 (6.4–7.9) 0.004 
Overweight (25.1–30.0) 5.3 (4.1–6.4)  4.6 (3.1–6.2)  7.1 (6.0–8.1) 0.022 
Obese (>30.0) 5.2 (3.3–7.1)  5.1 (3.5–6.6)  7.2 (5.5–8.9) 0.136 
Age at presentation (years)     
18–36 5.7 (4.7–6.7)  4.5 (0.8–8.2)  8.1 (6.7–9.6) 0.011 
37–47 4.9 (4.0–5.9)  8.4 (5.8–11.1)  7.2 (6.0–8.4) 0.002 
48–60 6.3 (4.9–7.6)  5.8 (4.1–7.5)  7.1 (6.1–8.0) 0.378 
≥61 4.3 (2.6–5.9)  4.0 (3.0–4.9)  6.3 (5.2–7.5) 0.008 
Etiology of hyperthyroidism     
Graves’ disease 5.9 (5.1–6.8)  9.1 (7.0–11.3)  8.6 (7.7–9.5) <0.001 
Toxic nodular 
hyperthyroidism 3.4 (1.1–5.7)  3.7 (2.6–4.8)  6.0 (4.4–7.7) 0.032 
Indeterminate etiology 5.1 (4.2–6.0)  4.4 (3.1–5.8)  5.9 (5.1–6.7) 0.160 
Smoking     
Non/ex-smokers 5.2 (4.5–5.8)  4.7 (3.7–5.7)  6.8 (6.1–7.4) <0.001 
Current smokers 6.2 (4.7–7.7)  7.1 (5.3–9.0)  8.2 (7.0–9.4) 0.088 
Serum fT4 at presentation      
(pmol/L) (ng/dL)     
≤22.0 ≤1.7 3.1 (-0.5–6.7)  2.5 (0.5–4.5)  3.8 (1.1–6.4) 0.745 
22.1–30.0  1.7–2.3 3.1 (2.0–4.3)  3.5 (2.5–4.4)  4.8 (3.8–5.8) 0.065 
20.1–40.0 2.3–3.1 4.4 (3.4–5.4)  5.1 (3.2–6.9)  6.4 (5.4–7.4) 0.020 
40.1–60.0 3.1–4.7 5.7 (4.6–6.7)  6.1 (3.1–9.1)  7.7 (6.7–8.8) 0.030 
≥60.1 ≥4.7 8.3 (6.9–9.7)  9.8 (7.2–12.4)  9.7 (8.2–11.1) 0.353 
Weight change at 
presentation     
Weight loss 6.8 (6.0–7.5)  7.1 (5.7–8.5)  8.5 (7.8–9.2) 0.002 
No weight change 2.8 (1.5–4.1)  3.4 (2.2–4.5)  3.4 (2.1–4.7) 0.722 
Weight gain 2.5 (0.6–4.4)  3.2 (1.3–5.2)  4.7 (2.6–6.8) 0.267 
No data recorded 3.8 (1.7–5.9)  1.8 (-0.2–3.9)  6.2 (4.7–7.6) 0.022 
ATD: Antithyroid drug treatment, BMI: Body Mass Index, fT4: free thyroxine, 95%CI: 95% 563 
confidence interval 564 
 565 
  566 
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Supplementary table 2: Weight gain in patients with well-defined Graves' disease or toxic 567 








Weight at presentation (kg)    
mean (SD) 80 (16.5) 68 (15.1) 70 (16.2) 
Duration of follow-up (months)    
mean (SD) 23 (8.6) 23 (8.8) 23 (8.7) 
BMI category at presentation (kg/m2)    
mean (SD) 26 (4.4) 26 (5.2) 26 (5.1) 
Healthy/underweight (≤25.0) 81 (47%) 305 (50%) 386 (49%) 
Overweight (25.1–30.0) 68 (40%) 195 (32%) 263 (34%) 
Obese (>30.0) 22 (13%) 111 (18%) 133 (17%) 
Age at presentation (years)    
18–36 54 (32%) 167 (27%) 221 (28%) 
37–47 47 (27%) 165 (27%) 212 (27%) 
48–60 44 (26%) 148 (24%) 192 (25%) 
60–90 26 (15%) 131 (21%) 157 (20%) 
Etiology of hyperthyroidism    
Graves’ disease 140 (82%) 444 (73%) 584 (75%) 
Toxic nodular hyperthyroidism 31 (18%) 167 (27%) 198 (25%) 
Reported weight change    
No weight change 26 (15%) 129 (21%) 155 (20%) 
Weight lost 121 (71%) 374 (61%) 495 (63%) 
Weight gain 9 (5%) 56 (9%) 65 (8%) 
No data 15 (9%) 52 (9%) 67 (9%) 
Smoking status    
Non-smoker 100 (58%) 468 (77%) 568 (73%) 
Smoker 71 (42%) 143 (23%) 214 (27%) 
Serum fT4 at presentation     
(pmol/L) (ng/dL)    
≤22.0 ≤1.7 2 (1%) 23 (4%) 25 (3%) 
22.1–30.0 1.7–2.3 39 (23%) 141 (23%) 180 (23%) 
30.1–40.0 2.3–3.1 25 (15%) 129 (21%) 154 (20%) 
40.1–60.0 3.1–4.7 55 (32%) 146 (24%) 201 (26%) 
≥60.1 ≥4.7 50 (29%) 172 (28%) 222 (28%) 
Treatment administered    
ATD only 59 (35%) 263 (43%) 322 (41%) 
131-I treatment (± ATD) 35 (20%) 104 (17%) 139 (18%) 
131-I (± ATD) and levothyroxine 77 (45%) 244 (40%) 321 (41%) 
Categorical data is presented as counts and proportions (%), continuous data as means and 569 
standard deviation (SD). BMI: Body Mass Index, fT4: free thyroxine, ATD: antithyroid drugs 570 
 571 
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Supplementary table 3: Sensitivity analysis using Generalised Estimating Equation model 573 
of weight gain during the treatment for hyperthyroidism including only patients with defined 574 






Interval P value 
  Lower Upper 
Treated with I-131 0.4 0.07 0.7 0.02 
On levothyroxine 0.5 0.3 0.8 <0.001 
Serial fT4 during follow-up     
(pmol/L) (ng/dL)     
≤10.0 ≤0.8 0.3 0.1 0.4 0.001 
10.1–22.0 0.8–1.7 0    
22.1–30.0 1.7–2.3 -0.6 -0.7 -0.4 <0.001 
30.1–40.0 2.3–3.1 -1.1 -1.4 -0.8 <0.001 
≥40.1 ≥3.1 -1.6 -1.9 -1.3 <0.001 
Serial serum TSH (mU/L)     
≤0.1 -0.8 -0.9 -0.6 <0.001 
0.11–0.30 -0.4 -0.6 -0.1 0.001 
0.31–4.50 0    
4.51–10.00 0.1 -0.04 0.3 0.1 
≥10.01 0.5 0.3 0.7 <0.001 
Age at presentation (years) 0.0 -0.02 0.02 0.7 
Initial weight (kg) 1.0 1.00 1.05 <0.001 
Length of follow-up (months) 0.4 0.4 0.5 <0.001 
Length of follow-up (months2) 0.0 -0.01 -0.01 <0.001 
Height (cm) 0.0 -0.05 0.03 0.5 
Female -0.9 -1.7 -0.05 0.04 
Smokers 0.6 -0.06 1.2 0.08 
Weight symptoms 
    
Same weight 0    
Gained weight 0.1 -0.8 1.1 0.8 
Lost weight 1.9 1.2 2.6 <0.001 
No data 0.3 -0.5 1.1 0.4 
Etiology of hyperthyroidism 
    
Graves' disease 0 
   
Toxic nodular  -0.5 -1.1 0.2 0.1 
 fT4 at presentation      
(pmol/L) (ng/dL)     
≤22 ≤1.7 -0.5 -1.7 0.6 0.4 
22.1–30.0 1.7–2.3 0    
30.1–40.0 2.3–3.1 0.1 -0.6 0.8 0.8 
40.1–60.0 3.1–4.7 0.8 0.07 1.5 0.03 
≥60.1 ≥4.7 2.1 1.3 2.8 <0.001 
The model presents the variables of interest in bold; the coefficients indicate predicted 576 
weight change (kg). TSH: thyroid stimulating hormone, fT4: free thyroxine 577 
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Supplementary table 4: Baseline characteristics of 26 users of steroid as recorded during the 580 







Weight (kg) at presentation 
mean (SD) 68.8 (12.2) 70.8 (16.3) 0.53 
Duration of follow-up (months) 
mean (SD) 24.2 (8.3) 22.6 (8.6) 0.33 
Sex    
Male 4 (15.4) 314 (23.3) 
0.34 
Female 22 (84.6) 1033 (76.7) 
BMI category at presentation (kg/m2)    
Healthy/underweight (≤25.0) 8 (30.8) 658 (48.8)  
Overweight (25.1–30.0) 11 (42.3) 439 (32.6) 0.18 
Obese (>30.0) 7 (26.9) 250 (18.6)  
Age at presentation (years)    
18–36 3 (11.5) 341 (25.3) 
0.015 
37–47 4 (15.4) 350 (26.0) 
48–60 6 (23.1) 338 (25.1) 
60–90 13 (50.0) 318 (23.6) 
Etiology of hyperthyroidism    
Graves’ disease 5 (19.2) 579 (43.0)  
Toxic nodular hyperthyroidism 5 (19.2) 193 (14.3) 0.05 
Indeterminate etiology 16 (61.5) 575 (42.7)  
Reported weight change    
No weight change 8 (30.8) 268 (19.9) 
0.51 
Weight loss 13 (50.0) 846 (62.8) 
Weight gain 2 (7.7) 108 (8.0) 
No data 3 (11.5) 125 (9.3) 
Smoking status    
Non-smoker 23 (88.5) 1021 (75.8) 
0.13 
Smoker 3 (11.5) 326 (24.2) 
Serum fT4 at presentation     
(pmol/L) (ng/dL)    
≤22.0 ≤1.7 0 (0.0) 57 (4.2) 
0.029 
22.1–30.0 1.7–2.3 9 (34.6) 319 (23.7) 
30.1–40.0 2.3–3.1 11 (42.3) 304 (22.6) 
40.1–60.0 3.1–4.7 2 (7.7) 355 (26.4) 
≥60.1 ≥4.7 4 (15.4) 312 (23.2) 
Treatment administered    
ATD only 6 (23.1) 567 (42.1) 
0.026 131-I treatment (± ATD) 9 (34.6) 220 (16.3) 




Supplementary table 5: Sensitivity analysis of multivariable model predicting the weight 583 
change following treatment for hyperthyroidism after exclusion of patients reporting at 584 








  Lower Upper 
 
Treated with I-131 0.4 0.2 0.6 <0.001 
On levothyroxine 0.6 0.4 0.8 <0.001 
Serial fT4 during follow-up     
(pmol/L) (ng/dL)     
≤10.0 ≤0.8 0.3 0.1 0.4 <0.001 
10.1–22.0 0.8–1.7 0    
22.1–30.0 1.7–2.3 -0.5 -0.7 -0.4 <0.001 
30.1–40.0 2.3–3.1 -1.1 -1.4 -0.8 <0.001 
≥40.1 ≥3.1 -1.6 -1.8 -1.3 <0.001 
Serial serum TSH (mIU/L)     
≤0.1 -0.8 -1.0 -0.7 <0.001 
0.11–0.30 -0.3 -0.5 -0.2 <0.001 
0.31–4.50 0    
4.51–10.00 0.1 0.02 0.3 0.02 
≥10.01 0.5 0.3 0.7 <0.001 
Age at presentation (years) 0.004 -0.01 0.02 0.57 
Initial weight (kg) 1.012 0.995 1.029 <0.001 
Length of follow-up (months) 0.40 0.37 0.44 <0.001 
Length of follow-up2 (months2) -0.008 -0.009 -0.007 <0.001 
Height (cm) -0.007 -0.036 0.021 0.60 
Female -0.9 -1.6 -0.3 0.003 
Smoking (current/non-smoker) -0.5 -1.0 0.006 0.05 
Reported weight change 
    
No weight change 0    
Weight gain 0.1 -0.6 0.8 0.75 
Weight lost 1.9 1.4 2.4 <0.001 
No data 0.7 -0.05 1.5 0.07 
Aetiology of hyperthyroidism 
    
Graves' disease 0 
   
Toxic nodular  -0.6 -1.2 0.02 0.06 
Indeterminate -0.7 -1.2 -0.2 0.003 
 fT4 at presentation  
    
(pmol/L) (ng/dL)     
≤22.0 ≤1.7 -0.2 -1.0 0.5 0.56 
22.1–30.0 1.7–2.3 0 
   
30.1–40.0 2.3–3.1 0.5 0.04 1.04 0.03 
40.1–60.0 3.1–4.7 1.3 0.8 1.8 <0.001 
≥60.1 ≥4.7 2.4 1.7 3.1 <0.001 
The model presents the variables of interest in bold; the coefficients indicate predicted 586 
weight change (kg); the reference category is underlined. TSH: thyroid stimulating 587 
hormone, fT4: free thyroxine 588 
 589 
